Le Lézard
Classified in: Environment, Science and technology, Business, Covid-19 virus
Subjects: ERN, ERP

SunPower Reports First Quarter 2023 Results


RICHMOND, Calif., May 3, 2023 /PRNewswire/ -- SunPower Corp. (NASDAQ:SPWR), a leading solar technology and energy services provider, today announced financial results for the first quarter, ending April 2, 2023.

"We exited the first quarter with high customer growth, significant new financing commitments, and unprecedented retrofit backlog driven by our efforts securing customers under NEM 2.0. This progress, despite challenging weather in California, validates the strength of the residential solar market and SunPower's ability to capture growing demand," said Peter Faricy, SunPower CEO. "As retail electricity rates continue to rise and consumers urgently seek a more affordable and reliable source of energy, the solar value proposition remains strong."

FIRST QUARTER BUSINESS HIGHLIGHTS

World-class customer experience

Best, most affordable products

Growth

Digital innovation

World-class financial solutions

 

1

Based on average of BBB, Yelp, ConsumerAffairs, BestCompany, Google, SolarReviews and EnergySage reviews scores as of 3/31/23

 

Financial Highlights


($ Millions, except percentages, residential
customers, and per-share data)

1st Quarter 2023

4th Quarter 2022

1st Quarter 2022

GAAP revenue from continuing operations

$440.9

$497.3

$350.3

GAAP gross margin from continuing operations

14.5 %

21.0 %

20.6 %

GAAP net (loss) income from continuing operations

$(50.7)

$7.6

$(2.2)

GAAP net (loss) income from continuing operations
per diluted share

$(0.29)

$0.04

$(0.01)

Non-GAAP revenue from continuing operations1

$442.5

$492.4

$336.1

Non-GAAP gross margin from continuing operations1

17.1 %

21.3 %

21.7 %

Non-GAAP net (loss) income from continuing
operations1, 3

$(12.5)

$26.2

$2.9

Non-GAAP net (loss) income from continuing
operations per diluted share1, 3

$(0.07)

$0.15

$0.02

Adjusted EBITDA1

$0.6

$36.2

$11.2

Residential customers

531,300

510,400

443,800

Cash2

$116.5

$377.0

$142.3




The sale of our C&I Solutions business met the criteria for classification as "discontinued operations" in accordance with the guidance in ASC 205-20, Discontinued Operations, beginning the first quarter of fiscal 2022. For all periods presented, the financial results of C&I Solutions are excluded in the table above.



1

Information about SunPower's use of non-GAAP financial information, including a reconciliation to U.S. GAAP, is provided under "Use of Non-GAAP Financial Measures" below.



2

Includes cash and cash equivalents, excluding restricted cash.



3

Non-GAAP results for fiscal 2022 have been recast to exclude the mark-to-market loss (gain) related to our interest rate swaps which are recorded within "interest expense" in our condensed consolidated statement of operations.

 

2023 Financial Outlook
SunPower affirmed 2023 guidance of $2,450?$2,900 Adjusted EBITDA per customer before platform investment and 90,000?110,000 incremental customers, resulting in $125?$155 million Adjusted EBITDA for the year.

Earnings Conference Call Information
SunPower will discuss its first quarter 2023 financial results on Wednesday, May 3 at 8:00 a.m. Eastern Time. Analysts intending to participate in the Q&A session must register for a personal link and dial-in at https://register.vevent.com/register/BIa4c7eb85f74b4d2da88bb20026d52c3c. The live audio webcast and supplemental financial information will be available on SunPower's investor website at http://investors.sunpower.com/events.cfm.

About SunPower 
SunPower (NASDAQ: SPWR) is a leading solar technology and energy services provider in North America. SunPower offers solar + storage solutions designed and warranted by one company that give customers control over electricity consumption and resiliency during power outages while providing cost savings. For more information, visit www.sunpower.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: (a) expectations regarding demand and our future performance based on backlog, bookings, projected consumer demand, and pipelines in our sales channels and for our products, and our ability to meet consumer demand; (b) our plans and expectations with respect to our strategic partnerships and initiatives, including our relationship with OhmConnect, our dealer accelerator program, and suppliers, and the anticipated business and financial impacts thereof; (c) our strategic plans and areas of investment and focus, both current and future, and expectations for the results thereof, including improved customer experience, lease and loan funding capacity, increased installation capacity, and development of new products and services; (d) our expectations regarding projected demand and growth in 2023 and beyond, our positioning for future success, and our ability to capture demand and deliver long-term value to our shareholders; (e) our expectations for industry trends and factors, and the impact thereof on our business and strategic plans; (f) the availability and sufficiency of the supply of products and raw materials to meet consumer demand; and (g) our guidance for fiscal year 2023, including Adjusted EBITDA per customer, incremental customers, and Adjusted EBITDA, as well as platform investments and related assumptions.

These forward-looking statements are based on our current assumptions, expectations, and beliefs and involve substantial risks and uncertainties that may cause results, performance, or achievement to materially differ from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: (1) regulatory changes and the availability of economic incentives promoting use of solar energy; (2) potential disruptions to our operations and supply chain that may result from epidemics or natural disasters, including impacts of the COVID-19 pandemic, and other factors; (3) competition in the solar and general energy industry, supply chain constraints, interest rates, inflation, and pricing pressures; (4) changes in public policy, including the imposition and applicability of tariffs and duties; (5) our dependence on sole- or limited-source supply relationships, including for our solar panels and other components of our products; (6) risks related to the introduction of new or enhanced products, including potential technical challenges, lead times, and our ability to match supply with demand while maintaining quality, sales, and support standards; (7) the success of our ongoing research and development efforts and our ability to commercialize new products and services, including products and services developed through strategic partnerships; (8) our liquidity, indebtedness, and ability to obtain additional financing for our projects and customers; and (9) challenges managing our acquisitions, joint ventures, and partnerships, including our ability to successfully manage acquired assets and supplier relationships. A detailed discussion of these factors and other risks that affect our business is included in filings we make with the Securities and Exchange Commission (SEC) from time to time, including our most recent report on Form 10-K, particularly under the heading "Risk Factors." Copies of these filings are available online from the SEC or on the SEC Filings section of our Investor Relations website at investors.sunpower.com. All forward-looking statements in this press release are based on information currently available to us, and we assume no obligation to update these forward-looking statements in light of new information or future events.

©2023 SunPower Corporation. All rights reserved. SUNPOWER, SUNPOWER FINANCIAL, SUNVAULT, and the SUNPOWER logo are trademarks or registered trademarks of SunPower Corporation in the U.S.

 

SUNPOWER CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)



April 2, 2023


January 1, 2023

Assets




Current assets:




Cash and cash equivalents

$                    116,478


$                    377,026

Restricted cash and cash equivalents, current portion

9,634


9,855

Short-term investments

?


132,480

Accounts receivable, net

194,231


174,577

Contract assets

58,610


50,692

Inventories

381,847


316,815

Advances to suppliers, current portion

12,508


9,309

Prepaid expenses and other current assets

212,970


197,760

Total current assets

986,278


1,268,514





Restricted cash and cash equivalents, net of current portion

15,158


15,151

Property, plant and equipment, net

82,117


74,522

Operating lease right-of-use assets

36,302


36,926

Solar power systems leased, net

40,768


41,779

Goodwill

126,338


126,338

Other intangible assets, net

22,435


24,192

Other long-term assets

183,015


192,585

Total assets

$                 1,492,411


$                 1,780,007





Liabilities and Equity




Current liabilities:




Accounts payable

$                    225,143


$                    242,229

Accrued liabilities

164,210


145,229

Operating lease liabilities, current portion

11,589


11,356

Contract liabilities, current portion

161,289


144,209

Short-term debt

121,473


82,404

Convertible debt, current portion

?


424,919

Total current liabilities

683,704


1,050,346





Long-term debt

155,969


308

Operating lease liabilities, net of current portion

28,362


29,347

Contract liabilities, net of current portion

11,305


11,555

Other long-term liabilities

109,782


112,797

Total liabilities

989,122


1,204,353





Equity:




Common stock

175


174

Additional paid-in capital

2,839,233


2,855,930

Accumulated deficit

(2,116,859)


(2,066,175)

Accumulated other comprehensive income

11,573


11,568

Treasury stock, at cost

(231,717)


(226,646)

Total stockholders' equity

502,405


574,851

Noncontrolling interests in subsidiaries

884


803

Total equity

503,289


575,654

Total liabilities and equity

$                 1,492,411


$                 1,780,007

 

SUNPOWER CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

Total revenues


$         440,878


$         497,312


$         350,277

Total cost of revenues


376,767


392,664


277,968

Gross profit


64,111


104,648


72,309

Operating expenses:







Research and development


7,247


5,560


5,010

Sales, general, and administrative


90,881


82,160


76,996

Restructuring charges (credits)


?


?


627

(Income) expense from transition services agreement, net


(224)


1,356


266

Total operating expenses


97,904


89,076


82,899

Operating (loss) income


(33,793)


15,572


(10,590)

Other (expense) income, net:







Interest income


831


2,922


42

Interest expense


(5,678)


(6,342)


(5,044)

Other, net


(10,983)


(6,755)


1,444

Other (expense) income, net


(15,830)


(10,175)


(3,558)

(Loss) income from continuing operations before income taxes and equity
in earnings (losses) of unconsolidated investees


(49,623)


5,397


(14,148)

(Provision for) benefits from income taxes


(1,227)


2,856


11,643

Equity in earnings (losses) of unconsolidated investees


247


365


?

Net (loss) income from continuing operations


(50,603)


8,618


(2,505)

(Loss) income from discontinued operations before income taxes and
equity in earnings (losses) of unconsolidated investees


?


?


(26,298)

Benefits from (provision for) income taxes from discontinued operations


?


?


343

Net (loss) income from discontinued operations, net of taxes


?


?


(25,955)

Net (loss) income


(50,603)


8,618


(28,460)

Net (income) loss from continuing operations attributable to
noncontrolling interests


(81)


(1,005)


339

Net loss (income) from discontinued operations attributable to
noncontrolling interests


?


?


250

Net (income) loss attributable to noncontrolling interests


(81)


(1,005)


589

Net (loss) income from continuing operations attributable to stockholders


(50,684)


7,613


(2,166)

Net (loss) income from discontinued operations attributable to stockholders


?


?


(25,705)

Net (loss) income attributable to stockholders


$         (50,684)


$             7,613


$         (27,871)








Net (loss) income per share attributable to stockholders - basic:







Continuing operations


$             (0.29)


$               0.04


$             (0.01)

Discontinued operations


$                   ?


$                   ?


$             (0.15)

Net (loss) income per share ? basic


$             (0.29)


$               0.04


$             (0.16)








Net (loss) income per share attributable to stockholders - diluted:







Continuing operations


$             (0.29)


$               0.04


$             (0.01)

Discontinued operations


$                   ?


$                   ?


$             (0.15)

Net (loss) income per share ? diluted


$             (0.29)


$               0.04


$             (0.16)








Weighted-average shares:







Basic


174,528


174,231


173,376

Diluted


174,528


175,518


173,376

 

SUNPOWER CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)




THREE MONTHS ENDED



April 2, 2023


January 1,
2023


April 3, 2022

Cash flows from operating activities:







Net (loss) income


$         (50,603)


$             8,618


$         (28,460)

Adjustments to reconcile net (loss) income to net cash used in operating activities:







Depreciation and amortization (excluding amortization of cloud computing arrangements)


9,989


7,781


4,170

Amortization of cloud computing arrangements


1,673


1,723


495

Stock-based compensation


6,877


7,378


5,427

Non-cash interest expense


617


1,108


726

Equity in (earnings) losses of unconsolidated investees


(247)


(365)


?

Loss (gain) on equity investments


10,805


6,255


(1,315)

Unrealized loss (gain) on derivatives


3,334


11


?

Dividend from equity method investees


371


(13)


?

Deferred income taxes


(815)


(1,367)


(13,750)

Other, net


91


1,081


845

Changes in operating assets and liabilities:







Accounts receivable


(19,745)


2,643


(12,354)

Contract assets


(7,918)


(11,943)


(6,519)

Inventories


(65,032)


(88,562)


(35,081)

Project assets


?


?


2,892

Prepaid expenses and other assets


(12,199)


9,690


(86,502)

Operating lease right-of-use assets


2,710


2,833


2,415

Advances to suppliers


(3,198)


(2,877)


(2,222)

Accounts payable and other accrued liabilities


(26,557)


45,142


41,444

Contract liabilities


16,830


1,921


22,066

Operating lease liabilities


(2,063)


(2,673)


(3,027)

Net cash (used in) provided by operating activities


(135,080)


(11,616)


(108,750)

Cash flows from investing activities:







Purchases of property, plant and equipment


(11,943)


(11,849)


(8,636)

Investments in software development costs


(891)


(1,465)


(1,521)

Cash paid for equity investments under the Dealer Accelerator Program and
other


?


?


(7,000)

Proceeds from sale of equity investment


121,675


?


149,830

Cash paid for investments in unconsolidated investees


(1,454)


(2,431)


(154)

Dividend from equity method investees


149


13


?

Net cash provided by (used in) investing activities


107,536


(15,732)


132,519

Cash flows from financing activities:







Proceeds from bank loans and other debt


245,764


21,482


21,458

Repayment of bank loans and other debt


(48,146)


(15,271)


(23,944)

Distributions to noncontrolling interests and redeemable noncontrolling
interests attributable to residential projects


?


(9,201)


?

Repayment of convertible debt


(424,991)


?


?

Payments for financing leases


(775)


(666)


?

Purchases of stock for tax withholding obligations on vested restricted stock


(5,070)


(943)


(7,332)

Net cash (used in) provided by financing activities


(233,218)


(4,599)


(9,818)

Net (decrease) increase in cash, cash equivalents, and restricted cash


(260,762)


(31,947)


13,951

Cash, cash equivalents and restricted cash, beginning of period


402,032


433,979


148,613

Cash, cash equivalents, and restricted cash, end of period


$         141,270


$         402,032


$         162,564








Reconciliation of cash, cash equivalents, and restricted cash to the condensed
consolidated balance sheets, including discontinued operations:







Cash and cash equivalents


$         116,478


$         377,026


$         142,250

Restricted cash and cash equivalents, current portion


9,634


9,855


681

Restricted cash and cash equivalents, net of current portion


15,158


15,151


12,857

Cash, cash equivalents, and restricted cash from discontinued operations


?


?


6,776

Total cash, cash equivalents, and restricted cash


$         141,270


$         402,032


$         162,564








Supplemental disclosure of cash flow information:







Property, plant and equipment acquisitions funded by liabilities (including
financing leases)


$             3,505


$             3,298


$                922

Right-of-use assets obtained in exchange of lease obligations


2,086


1,464


877

Net working capital settlement related to C&I Solutions sale


23,880


?


?

Cash paid for interest


11,969


741


9,874

Cash paid for income taxes


184


2,250


250

 

Use of Non-GAAP Financial Measures

To supplement its consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the company uses non-GAAP measures that are adjusted for certain items from the most directly comparable GAAP measures. The specific non-GAAP measures listed below are: revenue; gross margin; net (loss) income; net (loss) income per diluted share; and adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA"). Management believes that each of these non-GAAP measures are useful to investors, enabling them to better assess changes in each of these key elements of the company's results of operations across different reporting periods on a consistent basis, independent of certain items as described below. Thus, each of these non-GAAP financial measures provide investors with another method to assess the company's operating results in a manner that is focused on its ongoing, core operating performance, absent the effects of these items. Management uses these non-GAAP measures internally to assess the business, its financial performance, current and historical results, as well as for strategic decision-making and forecasting future results. Many of the analysts covering the company also use these non-GAAP measures in their analysis. Given management's use of these non-GAAP measures, the company believes these measures are important to investors in understanding the company's operating results as seen through the eyes of management. These non-GAAP measures are not prepared in accordance with GAAP or intended to be a replacement for GAAP financial data; and therefore, should be reviewed together with the GAAP measures and are not intended to serve as a substitute for results under GAAP, and may be different from non-GAAP measures used by other companies.

We exclude the following adjustments from our non-GAAP financial measures:

Non-GAAP Adjustments Based on International Financial Reporting Standards ("IFRS")

The company's non-GAAP results include adjustments under IFRS that are consistent with the adjustments made in connection with the company's internal reporting process as part of its status as a subsidiary and equity method investee of TotalEnergies SE, a foreign public registrant that reports under IFRS. Differences between GAAP and IFRS reflected in the company's non-GAAP results are further described below. In these situations, management believes that IFRS enables investors to better evaluate the company's performance, and assists in aligning the perspectives of the management with those of TotalEnergies SE.

Other Non-GAAP Adjustments

For more information about these non-GAAP financial measures, please see the tables captioned "Reconciliations of GAAP Measures to Non-GAAP Measures" set forth at the end of this release, which should be read together with the preceding financial statements prepared in accordance with GAAP.

 

SUNPOWER CORPORATION

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES

(In thousands, except percentages and per share data)

(Unaudited)


Adjustments to Revenue: 




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

GAAP revenue


$              440,878


$              497,312


$              350,277

Other adjustments:







Results of operations of businesses exited/to be exited


(759)


(4,893)


(14,208)

Mark-to-market loss (gain) on interest rate swaps


2,425


?


?

Non-GAAP revenue


$              442,544


$              492,419


$              336,069

 

Adjustments to Gross Profit Margin: 




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

GAAP gross profit from continuing operations


$            64,111


$          104,648


$            72,309

Other adjustments:







Results of operations of businesses exited/to be exited


7,890


(403)


(260)

Transition costs


262


(321)


378

(Gain) loss on sale and impairment of residential lease assets


(267)


(268)


(279)

Stock-based compensation expense


1,238


1,257


899

Business reorganization costs


?


?


?

Transaction-related costs


?


?


?

Mark-to-market loss (gain) on interest rate swaps


2,425


?


?

Non-GAAP gross profit


$            75,659


$          104,913


$            73,047








GAAP gross margin (%)


14.5 %


21.0 %


20.6 %

Non-GAAP gross margin (%)


17.1 %


21.3 %


21.7 %

 

Adjustments to Net (Loss) Income: 




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

GAAP net (loss) income from continuing operations attributable to stockholders


$              (50,684)


$                  7,613


$                (2,166)

Adjustments based on IFRS:







Mark-to-market loss (gain) on equity investments


10,805


6,255


(1,315)

Other adjustments:







Results of operations of businesses exited/to be exited


9,810


708


2,933

(Gain) loss on sale and impairment of residential lease assets


(267)


(268)


(279)

Litigation


570


1,242


177

Stock-based compensation expense


6,844


7,372


5,329

Amortization of intangible assets and software


2,786


2,780


1,978

Transaction-related costs


644


44


964

Transition costs


3,119


3,599


1,469

Business reorganization costs


?


1


?

Restructuring charges (credits)


?


?


186

Acquisition-related costs


3


114


5,808

Equity (income) loss from unconsolidated investees


(247)


(364)


?

Mark-to-market loss (gain) on interest rate swaps


3,334


11


?

Tax effect


790


(2,858)


(12,186)

Non-GAAP net (loss) income attributable to stockholders


$              (12,493)


$                26,249


$                  2,898

 

Adjustments to Net (Loss) Income per diluted share:




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

Net (loss) income per diluted share







Numerator:







GAAP net (loss) income available to common stockholders1


$              (50,684)


$                  7,613


$                (2,166)








Non-GAAP net (loss) income available to common stockholders1


$              (12,493)


$                26,249


$                  2,898








Denominator:







GAAP weighted-average shares


174,258


174,231


173,376

Effect of dilutive securities:







Restricted stock units


?


1,287


?

GAAP dilutive weighted-average common shares:


174,258


175,518


173,376








Non-GAAP weighted-average shares


174,258


174,231


173,376

Effect of dilutive securities:







Restricted stock units


?


1,287


1,399

Non-GAAP dilutive weighted-average common shares1


174,258


175,518


174,775








GAAP dilutive net (loss) income per share - continuing operations


$                  (0.29)


$                    0.04


$                  (0.01)

Non-GAAP dilutive net (loss) income per share - continuing operations


$                  (0.07)


$                    0.15


$                    0.02



1

In accordance with the if-converted method, net (loss) income available to common stockholders excludes interest expense related to the 4.00% debentures if the debentures are considered converted in the calculation of net (loss) income per diluted share. If the conversion option for a debenture is not in the money for the relevant period, the potential conversion of the debenture under the if-converted method is excluded from the calculation of non-GAAP net income (loss) per diluted share.

 

Adjusted EBITDA:




THREE MONTHS ENDED



April 2, 2023


January 1, 2023


April 3, 2022

GAAP net (loss) income from continuing operations attributable to stockholders


$              (50,684)


$                  7,613


$                (2,166)

Adjustments based on IFRS:







Mark-to-market loss (gain) on equity investments


10,805


6,255


(1,315)

Other adjustments:







Results of operations of businesses exited/to be exited


9,810


708


2,933

(Gain) loss on sale and impairment of residential lease assets


(267)


(268)


(279)

Litigation


570


1,242


177

Stock-based compensation expense


6,844


7,372


5,329

Amortization of intangible assets and software


2,786


2,780


1,978

Transaction-related costs


644


44


964

Transition costs


3,119


3,599


1,469

Business reorganization costs


?


1


?

Restructuring charges (credits)


?


?


186

Acquisition-related costs


3


114


5,808

Equity (income) loss from unconsolidated investees


(247)


(364)


?

Mark-to-market loss (gain) on CS interest rate swaps


3,334


11


?

Cash interest expense, net of interest income


3,996


3,469


4,878

Provision for (benefit from) income taxes


1,196


(2,883)


(11,676)

Depreciation


8,677


6,476


2,873

Adjusted EBITDA


$                     586


$                36,169


$                11,159

 

FY 2023 GUIDANCE

(in thousands)

FY 2023

Residential Customers

90,000 - 110,000

Residential Adjusted EBITDA/Customer1

$2,450 - $2,900

Adjusted EBITDA2

$125 million - $155 million

Net Loss (GAAP)

($31) million - ($1) million

  1. Excluding Product & Digital operating expenses for Residential only.

  2. Adjusted EBITDA guidance for FY 2023 includes net adjustments that decrease GAAP net loss by approximately $156 million primarily relating to the following adjustments: stock-based compensation expense, results of operations of businesses exited/to be exited, mark-to-market (gain) loss on equity investments, net, amortization of intangible assets and software, interest expense, depreciation, income taxes, and other non-recurring adjustments.

 

SOURCE SunPower Corp.


These press releases may also interest you

1 jun 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with...

1 jun 2024
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today...



News published on and distributed by: